Followers | 62 |
Posts | 9562 |
Boards Moderated | 0 |
Alias Born | 03/29/2015 |
Friday, March 29, 2024 11:57:10 AM
I would love for the above scenario to happen. If it does, then my net worth would dramatically increase.
For this to happen, NWBO management would have already have to have to transformed their mentality on the public relations issue and have been building connections with journalists and media companies and at the same time getting them to sit on what is already a huge news story. Maybe the right people in the media have been recruited to get the word out there as soon as MHRA hits and are holding their fire with good discipline for the moment of maximum impact.
What is equally likely is that NWBO is going to be afraid to 'front run the FDA' and will just let the media cover or not cover the story like NWBO did with JAMA and TLD before it.
At a minimum, even if NWBO stays true to form and avoids the pivot to active and clear communication everyone hopes for (whether they are honest about that or not) I believe that approval and the prospect of real revenue and with no compassionate use or Hospital Exemption-style BS will get enough of the market and maybe the media to pay attention.
Without NWBO amplifying MHRA approve there would be the risk that MHRA approval will not result in the gains we would like to see, but even so, I don't think we'll see a May 10th style reversal of fortunes.
Instead we will see the share price going a lot higher (and above all else) staying a lot higher than it is today, permanently this time.
As nice as that is in the short run, in the long run, having a higher SP will at least blunt the impact of continued dilution as we fully spin up in the UK and bring in revenue and as we march toward FDA approval (with the optics of rich Americans flying to the UK while poor patients left to languish in the States die, helping concentrate minds at the FDA and prevent last-minute shenanigans).
Recent NWBO News
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM